USA flag logo/image

An Official Website of the United States Government

Cardiovascular drug target identification via disordered protein analysis focus

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85793
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
HL083566
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Kinetics Inc
6201 La Pas Trail Suite 160 Indianapolis, IN 46268-4869
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Cardiovascular drug target identification via disordered protein analysis focus
Agency: HHS
Contract: 1R43HL083566-01A2
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): A certain type of protein-protein interaction can be blocked using small molecules. This type of interaction involves a disorder-to-order transition of a molecular recognition element on one protein binding to a recept or site on another. Application of our proprietary bioinformatics software called PONDR(r) to a substantial set of cardiovascular disease (CVD)-associated proteins revealed that greater than 60% of these proteins are likely to contain disordered regions o f substantial size and these regions contain a large number of molecular recognition elements. To exploit these preliminary findings, we will construct an annotated database of CVD proteins, CardioVascular DisProt (CVD DisProt), correlating disord er/order to proteins' functions. This new database will contain disorder/order predictions and existing structural knowledge correlated with collected functions of CVD-associated proteins and augmented with information of protein interaction networks. Ne xt, our preliminary bioinformatics tools will be enhanced for the purpose of identifying druggable protein-protein interactions. The products developed in this project will form a new, powerful research tool, which will be used by pharmaceutical and biote chnology companies to improve prioritization of novel drug targets. CVD researchers could use relationships between function and order/disorder propensity to discover new proteins involved in signaling pathways of interest. Structural genomics centers wo uld find CVD DisProt indispensable as a source of biologically relevant, ordered domains for structure determination. Finally, and most importantly, using the enhanced PONDR(r) tools, the CVD DisProt will be datamined to yield a ranked list of druggable p rotein-protein interactions. This will provide the starting point for a novel pathway for drug discovery.

Principal Investigator:

Vladimir N. Uversky
3172808737
MAIN@MOLECULARKINETICS.COM

Business Contact:

Ya Y. J
main@molecularkinetics.com
Small Business Information at Submission:

MOLECULAR KINETICS, INC.
6201 La Pas Trail SUITE 160 INDIANAPOLIS, IN 46268

EIN/Tax ID: 911366111
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No